{"id":64552,"date":"2026-05-06T20:50:52","date_gmt":"2026-05-06T12:50:52","guid":{"rendered":"https:\/\/flcube.com\/?p=64552"},"modified":"2026-05-06T20:50:53","modified_gmt":"2026-05-06T12:50:53","slug":"senhwa-biosciences-launches-global-phase-i-ii-trial-of-first-in-class-pidnarulex-combined-with-beones-tislelizumab-in-solid-tumors-including-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64552","title":{"rendered":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#8217;s Tislelizumab in Solid Tumors Including Pancreatic Cancer"},"content":{"rendered":"\n<p><strong>Senhwa Biosciences, Inc. (TPE: 6492)<\/strong> announced on May 5, 2026, the initiation of a <strong>global, multi-center clinical trial<\/strong> evaluating its first-in-class investigational drug <strong>Pidnarulex (CX-5461)<\/strong> in combination with <strong>BeOne Medicines&#8217;<\/strong> marketed PD-1 inhibitor <strong>tislelizumab<\/strong> across multiple advanced or metastatic solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design-amp-indications\">Clinical Trial Design &amp; Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Type<\/strong><\/td><td>Global, multi-center Phase I\/II<\/td><\/tr><tr><td><strong>Combination Partner<\/strong><\/td><td>Tislelizumab (BeOne Medicines&#8217; PD-1 inhibitor)<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Pancreatic cancer, colorectal cancer, melanoma<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced or metastatic solid tumors<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Multiple international clinical sites<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The trial represents a strategic collaboration between Senhwa&#8217;s novel mechanism and BeOne&#8217;s established immunotherapy platform to address difficult-to-treat solid tumors with high unmet medical need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-dual-mechanism-of-action\">Drug Profile &amp; Dual Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Pidnarulex (CX-5461) \u2013 first-in-class investigational agent<\/li>\n\n\n\n<li><strong>Primary Mechanism:<\/strong> Inhibition of ribosomal RNA synthesis, suppressing tumor cell proliferation<\/li>\n\n\n\n<li><strong>Secondary Mechanism:<\/strong> Stabilization of G-quadruplex structures, inducing DNA damage<\/li>\n\n\n\n<li><strong>Immunological Effect:<\/strong> Activation of the cGAS\u2013STING pathway<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Dual action targets both tumor cells and immune microenvironment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence-supporting-combination-strategy\">Preclinical Evidence Supporting Combination Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Effect<\/th><th>Mechanism<\/th><th>Therapeutic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Tumor Microenvironment Remodeling<\/strong><\/td><td>CX-5461-induced changes<\/td><td>Creates more immunogenic tumor environment<\/td><\/tr><tr><td><strong>Increased TILs<\/strong><\/td><td>Enhanced tumor-infiltrating lymphocytes<\/td><td>Improves immune cell access to tumor<\/td><\/tr><tr><td><strong>PD-L1 Upregulation<\/strong><\/td><td>Increased checkpoint expression<\/td><td>Potentiates PD-1 inhibitor activity<\/td><\/tr><tr><td><strong>Combination Synergy<\/strong><\/td><td>Dual targeting of tumor + immune system<\/td><td>Potential backbone for immunotherapy regimens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Preclinical and translational studies have demonstrated that CX-5461 effectively remodels the tumor microenvironment, increases tumor-infiltrating lymphocytes (TILs), and upregulates PD-L1 expression, positioning it as a potential backbone agent in combination immunotherapy strategies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-implications\">Strategic Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer Focus:<\/strong> Addresses one of oncology&#8217;s most challenging indications with limited treatment options<\/li>\n\n\n\n<li><strong>Immunotherapy Enhancement:<\/strong> Novel approach to overcome resistance to existing checkpoint inhibitors<\/li>\n\n\n\n<li><strong>Global Development Strategy:<\/strong> Positions Senhwa for international regulatory pathways and commercial opportunities<\/li>\n\n\n\n<li><strong>Partnership Model:<\/strong> Leverages BeOne&#8217;s established tislelizumab commercial infrastructure<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> CX-5461&#8217;s unique dual mechanism offers differentiation from existing targeted therapies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,62,29,18,4725],"class_list":["post-64552","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-beone-medicines","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-pd-1-l1","tag-senhwa-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#039;s Tislelizumab in Solid Tumors Including Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines&#039; marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64552\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#039;s Tislelizumab in Solid Tumors Including Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines&#039; marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64552\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T12:50:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T12:50:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Senhwa Biosciences Launches Global Phase I\\\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#8217;s Tislelizumab in Solid Tumors Including Pancreatic Cancer\",\"datePublished\":\"2026-05-06T12:50:52+00:00\",\"dateModified\":\"2026-05-06T12:50:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeOne Medicines\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"PD-1\\\/L1\",\"Senhwa Biosciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64552#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64552\",\"name\":\"Senhwa Biosciences Launches Global Phase I\\\/II Trial of First-in-Class Pidnarulex Combined with BeOne's Tislelizumab in Solid Tumors Including Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-06T12:50:52+00:00\",\"dateModified\":\"2026-05-06T12:50:53+00:00\",\"description\":\"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64552\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64552#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senhwa Biosciences Launches Global Phase I\\\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#8217;s Tislelizumab in Solid Tumors Including Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne's Tislelizumab in Solid Tumors Including Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64552","og_locale":"en_US","og_type":"article","og_title":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne's Tislelizumab in Solid Tumors Including Pancreatic Cancer","og_description":"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.","og_url":"https:\/\/flcube.com\/?p=64552","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-06T12:50:52+00:00","article_modified_time":"2026-05-06T12:50:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64552#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64552"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#8217;s Tislelizumab in Solid Tumors Including Pancreatic Cancer","datePublished":"2026-05-06T12:50:52+00:00","dateModified":"2026-05-06T12:50:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64552"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeOne Medicines","Clinical trial approval \/ initiation","Combination therapy","PD-1\/L1","Senhwa Biosciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64552#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64552","url":"https:\/\/flcube.com\/?p=64552","name":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne's Tislelizumab in Solid Tumors Including Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-06T12:50:52+00:00","dateModified":"2026-05-06T12:50:53+00:00","description":"Senhwa Biosciences, Inc. (TPE: 6492) announced on May 5, 2026, the initiation of a global, multi-center clinical trial evaluating its first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' marketed PD-1 inhibitor tislelizumab across multiple advanced or metastatic solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64552#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64552"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64552#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Senhwa Biosciences Launches Global Phase I\/II Trial of First-in-Class Pidnarulex Combined with BeOne&#8217;s Tislelizumab in Solid Tumors Including Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64552"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64552\/revisions"}],"predecessor-version":[{"id":64553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64552\/revisions\/64553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}